Skip to Main Content

Three drug makers — including Teva Pharmaceutical (TEVA) and Endo International (ENDP) — agreed to pay nearly $70 million to the state of California to settle allegations of striking so-called pay-to-delay agreements that kept lower-cost generic versions of their medicines from entering the market.

In announcing the settlements, California Attorney General Xavier Becerra maintained the arrangement included the largest such settlement received by any state, as well as the only ones to secure an injunction against any future pay-for-delay agreements.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED